Ginsenoside Rg3 attenuates tumor angiogenesis via inhibiting bioactivities of endothelial progenitor cells

Cancer Biology and Therapy

Volumn 13, Issue 7, 2012, Pages 504-515

  Kim, Jae Won ^b   Jung, Seok Yun ^a   Kwon, Yi Hong ^b   Lee, Jun Hee ^a   Lee, You Mie ^c   Lee, Boo Yong ^b   Kwon, Sang Mo ^a  

^a Pusan National University School of Medicine   (South Korea)

^b CHA University   (South Korea)

^c Kyungpook National University   (South Korea)

Author keywords

Anti angiogenesis; Endothelial progenitor cells; Ginsenoside Rg3; Tumor angiogenesis; VEGF signaling

Indexed keywords

GINSENOSIDE RG 3; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; ENDOTHELIAL PROGENITOR CELL; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CARCINOMA, LEWIS LUNG; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; ENDOTHELIAL CELLS; GENE EXPRESSION; GINSENOSIDES; HUMANS; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; STEM CELLS; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861176603     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.19599     Document Type: Article

References (41)

1. Cooney MM, van Heeckeren W, Bhakta S, Ortiz J, Remick SC. Drug insight: vascular disrupting agents and angiogenesis - novel approaches for drug delivery. Nat Clin Pract Oncol 2006; 3:682-92; PMID:17139319; http://dx.doi.org/10.1038/ncponc0663.
2. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3:401-10; PMID:12778130; http://dx.doi.org/10.1038/nrc1093.
3. Skowasch D, Jabs A, Lüderitz B, Bauriedel G. Bone marrow-derived cells and vascular growth. Circ Res 2004; 94:71; PMID:15117831; http://dx.doi. org/10.1161/01.RES.0000126418.31311.F8.
4. Du R, Lu KV, Petritsch C, Liu P, Ganss R, PasseguéE, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008; 13:206-20; PMID:18328425; http://dx.doi. org/10.1016/j.ccr.2008.01.034.
5. Zheng H, Fu G, Dai T, Huang H. Migration of endothelial progenitor cells mediated by stromal cell-derived factor-1alpha/CXCR4 via PI3K/Akt/eNOS signal transduction pathway. J Cardiovasc Pharmacol 2007; 50:274-80; PMID:17878755; http://dx.doi. org/10.1097/FJC.0b013e318093ec8f.
6. Shojaei F, Wu X, Qu X, Kowanetz M, Yu L, Tan M, et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci USA 2009; 106:6742-7; PMID:19346489; http://dx.doi.org/10.1073/pnas.0902280106.
7. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7:1194-201; PMID:11689883; http://dx.doi. org/10.1038/nm1101-94.
8. Nolan DJ, Ciarrocchi A, Mellick AS, Jaggi JS, Bambino K, Gupta S, et al. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev 2007; 21:1546-58; PMID:17575055; http://dx.doi.org/10.1101/gad.436307.
9. Gao DC, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 2008; 319:195-8; PMID:18187653; http://dx.doi.org/10.1126/ science.1150224.
10. Kopp HG, Ramos CA, Rafii S. Contribution of endothelial progenitors and proangiogenic hematopoietic cells to vascularization of tumor and ischemic tissue. Curr Opin Hematol 2006; 13:175-81; PMID:16567962; http://dx.doi.org/10. 1097/01. moh.0000219664.26528.da.
11. Asahara T, Takahashi T, Masuda H, Kalka C, Chen DH, Iwaguro H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999; 18:3964-72; PMID:10406801; http://dx.doi.org/10.1093/emboj/18.14.3964.
12. Gasparini G, Longo R, Toi M, Ferrara N. Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol 2005; 2:562-77; PMID:16270097; http://dx.doi.org/10.1038/ncponc0342.
13. Kerr DJ. Targeting angiogenesis in cancer: clinical development of bevacizumab. Nat Clin Pract Oncol 2004; 1:39-43; PMID:16264798; http://dx.doi. org/10.1038/ncponc0026.
14. Perabo FG, Von Löw EC, Ellinger J, von Rücker A, Müller SC, Bastian PJ. Soy isoflavone genistein in prevention and treatment of prostate cancer. Prostate Cancer Prostatic Dis 2008; 11:6-12; PMID:17923857; http://dx.doi.org/10.1038/sj.pcan.4501000.
15. Wong VK, Cheung SS, Li T, Jiang ZH, Wang JR, Dong H, et al. Asian ginseng extract inhibits in vitro and in vivo growth of mouse lewis lung carcinoma via modulation of ERK-p53 and NFκB signaling. J Cell Biochem 2010; 111:899-910; PMID:20665661; http://dx.doi.org/10.1002/jcb.22778.
16. Surh YJ, Na HK, Lee JY, Keum YS. Molecular mechanisms underlying anti-tumor promoting activities of heat-processed Panax ginseng C.A. Meyer. J Korean Med Sci 2001; 16:38-41; PMID:11748375.
17. Liu CX, Xiao PG. Recent advances on ginseng research in China. J Ethnopharmacol 1992; 36:27-38; PMID:1501490; http://dx.doi.org/10.1016/0378- 8741(92)90057-X.
18. Zhang QY, Kang XM, Zhao WH. Antiangiogenic effect of low-dose cyclophosphamide combined with ginsenoside Rg3 on Lewis lung carcinoma. Biochem Biophys Res Commun 2006; 342:824-8; PMID:16499874; http://dx.doi.org/10.1016/j. bbrc.2006.02.044.
19. Yi C, Huang XB, Hou M. Experimental study on effect of chemotherapy combined ginsengnoside Rg3 in treating pulmonary carcinoma. Zhongguo Zhong Xi Yi Jie He Za Zhi 2005; 25:58-9; PMID:15719754.
20. Iishi H, Tatsuta M, Baba M, Uehara H, Nakaizumi A, Shinkai K, et al. Inhibition by ginsenoside Rg3 of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in Wistar rats. Clin Exp Metastasis 1997; 15:603-11; PMID:9344044; http://dx.doi. org/10.1023/A: 1018491314066.
21. Liu JW, Chen JX, Yu LH, Tian YX, Cui XY, Yan Q, et al. [Inhibitory effect of ginsenoside-Rg3 on lung metastasis of mouse melanoma transfected with ribonuclease inhibitor]. Zhonghua Zhong Liu Za Zhi 2004; 26:722-5; PMID:15733388.
22. Nagy JA, Chang SH, Dvorak AM, Dvorak HF. Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer 2009; 100:865-9; PMID:19240721; http://dx.doi.org/10.1038/sj.bjc.6604929.
23. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 2000; 55:15-35.
24. Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 2009; 6:569-79; PMID:19736552; http://dx.doi.org/10.1038/nrclinonc.2009.130.
25. Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009; 6:507-18; PMID:19636328; http://dx.doi.org/10.1038/nrclinonc.2009.110.
26. Iwaguro H, Yamaguchi J, Kalka C, Murasawa S, Masuda H, Hayashi S, et al. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation 2002; 105:732-8; PMID:11839630; http://dx.doi.org/10.1161/hc0602.103673.
27. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006; 313:1785-7; PMID:16990548; http://dx.doi.org/10.1126/ science.1127592.
28. Somanath PR, Razorenova OV, Chen JH, Byzova TV. Akt1 in endothelial cell and angiogenesis. Cell Cycle 2006; 5:512-8; PMID:16552185; http://dx.doi. org/10.4161/cc.5.5.2538.
29. Murphy DA, Makonnen S, Lassoued W, Feldman MD, Carter C, Lee WMF. Inhibition of tumor endothelial ERK activation, angiogenesis and tumor growth by sorafenib (BAY43-9006). Am J Pathol 2006; 169:1875-85; PMID:17071608; http://dx.doi.org/10.2353/ajpath.2006.050711.
30. Fang J, Zhou Q, Liu LZ, Xia C, Hu X, Shi X, et al. Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis 2007; 28:858-64; PMID:17071632; http://dx.doi. org/10.1093/carcin/bgl205.
31. Yi T, Cho SG, Yi Z, Pang X, Rodriguez M, Wang Y, et al. Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extra-cellular signal-regulated kinase signaling pathways. Mol Cancer Ther 2008; 7:1789-96; PMID:18644991; http://dx.doi.org/10.1158/1535-7163.MCT-08-0124.
32. Dvorak HF. Angiogenesis: update 2005. J Thromb Haemost 2005; 3:1835-42; PMID:16102050; http://dx.doi.org/10.1111/j.1538-7836.2005.01361.x.
33. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85:221-477.
34. Oh HK, Ha JM OE, Lee BH, Lee SK, Shim BS, et al. Tumor angiogenesis promoted by ex vivo differentiated endothelial progenitor cells is effectively inhibited by an angiogenesis inhibitor, TK1-2. Cancer Res 2007; 67:4851-9; PMID:17510415; http://dx.doi. org/10.1158/0008-5472.CAN-06-2979.
35. Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006; 312:1171-5; PMID:16728631; http://dx.doi. org/10.1126/science.1125950.
36. Nishimura H, Asahara T. Bone marrow-derived endothelial progenitor cells for neovascular formation. EXS 2005; 21:147-54; PMID:15617476; http://dx.doi. org/10.1007/3-7643-7311-3-10.
37. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 1995; 15:2612-24; PMID:7739542.
38. Ezhevsky SA, Nagahara H, Vocero-Akbani AM, Gius DR, Wei MC, Dowdy SF. Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb. Proc Natl Acad Sci USA 1997; 94:10699-704; PMID:9380698; http://dx.doi.org/10.1073/pnas.94.20.10699.
39. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 1998; 18:753-61; PMID:9447971.
40. Guo J, Schally AV, Zarandi M, Varga J, Leung PC. Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway. Reprod Biol Endocrinol 2010; 8:54; PMID:20509930; http://dx.doi.org/10.1186/1477-7827-8-54.
41. Yue PY, Wong DY, Ha WY, Fung MC, Mak NK, Yeung HW, et al. Elucidation of the mechanisms underlying the angiogenic effects of ginsenoside Rg(1) in vivo and in vitro. Angiogenesis 2005; 8:205-16; PMID:16328162; http://dx.doi.org/10. 1007/s10456-005-9000-2.